AIxMed Computational Cytology
by AIxMed
· Based in United States →
— Beyond Human Insight | AI-Driven Digital Cytology: Cancer Cells Have Nowhere to Hide
Regulatory Status Disclosed
Overview
AIxMed Computational Cytology is an AI-powered platform designed to enhance cytology insights for cancer diagnosis and monitoring. The platform currently offers AIxURO, an AI-assisted urine cytology imaging and reporting software package for bladder cancer diagnosis and surveillance.
- What it does: AIxURO identifies suspicious and atypical cells in non-invasive urine samples, adhering to The Paris System for Reporting Urinary Cytology (TPS) criteria. The platform digitizes 3D cytology samples, extracts clinical insights, and provides quantitative and qualitative data. It offers features such as ranked gallery presentation of abnormal cells, whole-slide image analysis, and detailed slide-level statistics.
- Who it is for: This tool is primarily for pathologists and cytotechnologists in care settings that perform cytology analysis, particularly for bladder cancer.
- How it fits a clinical or practice workflow: AIxMed’s platform integrates into existing digital pathology workflows and Laboratory Information Systems (LIS). It aims to support cytology review by automating the identification of suspicious cells, providing standardized data, and offering structured assisted workflows. This can involve rapid imaging of slides, AI-powered cell characterization, and digital marking and storage of abnormal cells.
- Notable capabilities: AIxURO is currently the only commercial AI product specifically for urinary cytology. It is designed to improve diagnostic accuracy and workflow efficiency in bladder cancer assessment. Studies suggest that AIxURO can improve sensitivity and negative predictive value for atypical urothelial cell (AUC) and suspicious for high-grade urothelial carcinoma (SHGUC) cases. AIxMed is also developing solutions for thyroid (AIxTHY), cervical (AIxPAP), and pulmonary (AIxPUL) cytology.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered computational platform for cytology
- Enhances cytology insights
- Improves workflows and quality of patient care
- Automatically identifies suspicious and atypical cells in digital images
- Digital marking and records storage of abnormal cells directly into EHR
- Rapid consultations with whole slide images and software
- Consistent quantitative and qualitative data
- Analyzes multiple Z-planes
- Presents abnormal cells in a Gallery View with criteria
- Views all cells and layers in one file
Use Cases
- Bladder cancer diagnosis and monitoring (AIxURO)
- Thyroid cancer detection and diagnosis (AIxTHY - coming soon)
- Cervical cancer screening (AIxPAP - coming soon)
- Lung cancer detection (AIxPUL - coming soon)
- Reducing bottlenecks and turnaround times in pathology labs
- Supporting personalized patient care in oncology
What Physicians Need to Know
LIS/LIMS Integration
AIxMed's computational cytology platform is designed to integrate into existing laboratory environments and can be integrated into Laboratory Information Systems (LIS) and digital pathology infrastructures.
Supported Assay Types
AIxMed's flagship application, AIxUROu2122, is specifically developed for the analysis of non-invasive urine cytology specimens for bladder cancer diagnosis, utilizing The Paris System for Reporting Urinary Cytology (TPS). They are expanding their digital cytology platform to include thyroid, cervical, and lung cancer applications (AIxTHY, AIxPAP).
QC/QA Features
The platform supports cytology review with automated prioritization and structured assisted workflows. AIxUROu2122 aims to improve diagnostic accuracy and workflow efficiency in bladder cancer assessment. It can also be used for modernizing cytology quality control (QC) through digital and AI tools, offering significant time savings with consistent results. AIxUROu2122 assists pathologists in making more confident diagnostic decisions by combining qualitative morphology with quantitative metrics.
Result Interpretation AI
AIxMed's AI-powered computational platform enhances cytology insights with quantitative and qualitative data. AIxUROu2122 leverages advanced AI to enhance traditional urine cytology analysis by identifying and highlighting suspicious and atypical cells, presenting them in a gallery view with criteria, and providing detailed quantitative analysis including N/C ratios and nucleus area measurements. The AI-powered analysis is trained on thousands of slides and cells. AIxMed's AI-assisted diagnosis has shown to significantly enhance diagnostic accuracy and consistency, particularly in complex cases involving atypical cells.
Critical Value Alerts
While the platform focuses on identifying suspicious and atypical cells and enhancing diagnostic accuracy, specific features for 'critical value alerts' as a distinct function are not explicitly detailed in the provided information. However, the system's ability to highlight and rank cells of interest for focused review and provide quantitative metrics could indirectly support the identification of critical findings.
Instrument Interfaces
AIxMed's digital cytology solution is compatible with various slide imaging systems (scanners) and Papanicolaou stained slide preparation methods (Cytospin, SurePath, ThinPrep, Direct).
Reference Range Intelligence
AIxUROu2122 aids in bladder cancer diagnosis using The Paris System for Reporting Urinary Cytology (TPS). It provides advanced slide-level and cell-level measurements to support structured review and evaluation, including TPS 2.0 morphology indicators.
Turnaround Time Impact
AIxMed's platform aims to improve workflows and quality of patient care. AIxUROu2122 is designed to improve workflow efficiency in bladder cancer assessment and can reduce diagnostic review time by 50-80%, accelerating the delivery of results. This leads to faster tissue processing and improved turnaround times.
Physician Tip
AIxMed's computational cytology platform, particularly AIxUROu2122, offers significant advantages for pathologists and cytotechnologists in cancer diagnosis and monitoring. Leverage the AI-powered analysis for automated prioritization and structured review of cytology slides, especially for challenging cases involving atypical cells. The system's ability to highlight and rank cells of interest, coupled with quantitative metrics like N/C ratios and nucleus area, can enhance diagnostic confidence and consistency. Integrating this tool can streamline workflows, potentially reducing review times and supporting earlier intervention for patients. Remember that AIxUROu2122 is currently for Research Use Only (RUO) for some applications, so understand its regulatory status for your specific use case.
AIxMed's digital cytology platform is designed for easy integration into existing laboratory workflows and digital pathology ecosystems. It is compatible with various slide imaging systems and Papanicolaou stained slide preparation methods. The platform can integrate with Laboratory Information Systems (LIS) and digital pathology infrastructures, allowing for key AI findings to be shared and providing a full audit trail. Partnerships with digital pathology providers like Lumea and PathNet demonstrate its ability to enhance existing platforms with AI-powered cytology solutions.
Details
| Category | Lab & Diagnostics, Oncology AI, Pathology AI |
| Pricing | Unknown — unknown |
| Deployment | Cloud-based |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Pending AI-estimated AIxMed's flagship application, AIxURO™, is currently available as a Research Use Only (RUO) application. The company has stated intentions to submit results to the FDA in the near future. While AIxMed's AIxURO solution is designed to assist in the analysis of non-invasive urine cytology specimens, aiming to improve diagnostic accuracy and workflow efficiency in bladder cancer assessment, it is not yet FDA cleared for diagnostic use. |
| Integrations | |
| EHR | Not specified |
| Specialties | Laboratory Medicine, Oncology, Pathology |
What the Web Says
AIxMed Computational Cytology, particularly its AIxUROu2122 platform, is an AI-powered solution designed to enhance the accuracy and efficiency of bladder cancer detection through urine cytology. It digitizes 3D cytology samples, extracts clinical insights, and aims to improve workflows and patient care. The platform is currently available for Research Use Only (RUO) and is not for use in diagnostic procedures.
Overall: PositiveStrengths
- Enhances cytology insights with quantitative and qualitative data.
- Improves workflow efficiency and consistency in cytology review.
- Reduces diagnostic review time by 50-80%.
- Potentially reduces the need for invasive procedures like cystoscopies, improving patient compliance and lowering healthcare costs.
- Provides automated prioritization, standardized data, and structured assisted workflows.
- Compatible with various slide imaging systems and Papanicolaou stained slide preparation methods.
Limitations
- Currently for Research Use Only (RUO) and not for diagnostic procedures.
- Limited public reviews available on platforms like G2 and Capterra.
- No specific negative reviews or opinions were found in the search results from physicians, healthcare IT, tech reviewers, or Reddit.
- Implementation can be complex and time-consuming.
- Data integration with existing hospital systems can be challenging.
- Requires significant institutional commitment and resources.
Based on reviews from: AIxMed, Inc., Webull, EIN Presswire, Vertex AI Search, G2
Last updated: 2026-08-25
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate AIxMed Computational Cytology
Press & Coverage
PR Newswire
AIxMed and Biopticka Laboratou0159 Announce Strategic Collaboration to Advance AI-Powered Cytology in Europe
AIxMed Inc. and Biopticka Laboratou0159 s.r.o. have partnered to integrate AIxMed's AIxUROu2122 solution for urine cytology into Biopticka's laboratory system, aiming to enhance bladder cancer detection accuracy and efficiency in Europe. AIxUROu2122 is currently a Research Use Only application.
2025-10
PR Newswire
AIxMed Partnership with Lumea Enhances Digital Pathology Platform with AI-Powered Urine Cytology Solution
AIxMed and Lumea announced a partnership to integrate AIxMed's AIxUROu2122 technology into Lumea's FDA-cleared digital pathology platform, aiming to improve bladder cancer diagnostics. This collaboration seeks to enhance diagnostic accuracy and workflow efficiency for urine cytology specimens.
2025-05
BioSpace
AIxMed and CorePlus Partner to study a Urine Cytology Workflow Solution
AIxMed and CorePlus have entered an agreement to conduct a pilot study applying AIxMed's AI algorithm to test a workflow solution for urine cytology, aiming to improve efficiency and precision in cancer diagnosis. This collaboration will provide an end-to-end solution for research-use only urine cytology analysis.
2024-04
The SaaS News
AIxMed Raises $2.75 Million in Funding
AIxMed secured $2.75 million in SAFE funding from existing investors to accelerate the development of its AI-powered digital cytology platform. The company's initial application, AIxURO, focuses on AI-assisted urine cytology for bladder cancer diagnosis and surveillance.
2023-04
AIxMed, Inc.
AIxURO URINE CYTOLOGY CLINICAL STUDIES
AIxMed highlights AI-Powered Urine Cytology: Redefining Diagnostic Precision and Workflow at PathNet, showcasing clinical studies related to their AIxURO solution.
2026-03
EINPresswire (via AIxMed, Inc.)
CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI
CorePlus and AIxMed are collaborating to provide 100% quality control on bladder cancer detection using AI, as highlighted in a news release.
2026-01
PR Newswire (via AIxMed, Inc.)
AIxMed and PathNet Partnership: Advancing Digital Pathology with AI-Powered Urine Cytology
AIxMed and PathNet announced a strategic partnership to advance digital pathology through AI-powered urine cytology.
2025-11
EINPresswire (via AIxMed, Inc.)
AIxMed and ASCT Partnership
AIxMed and ASCT have formed a partnership, as announced in a press release.
2025-11
Videos
Product demos, reviews, and walkthroughs for AIxMed Computational Cytology.
Loading videos...
Frequently Asked Questions
AIxMed's computational cytology platform is designed to integrate with existing digital pathology ecosystems and compatible slide imaging systems. It supports cytology review with automated prioritization and structured assisted workflows, aiming to enhance diagnostic accuracy and workflow efficiency.
Currently, AIxMed's flagship application, AIxUROu2122, which aids in bladder cancer diagnosis using The Paris System for Reporting Urinary Cytology (TPS), is available as a Research Use Only (RUO) application. It is not yet cleared for diagnostic procedures.
While AIxMed's AIxURO system is noted as a commercial AI product for urinary cytology, other AI companies like AIRA Matrix, Artera, Deepbio, Mindpeak, Paige AI, Panakeia, Primaa, Tempus, and Valar Labs are also developing AI solutions for digital pathology, often with different focuses such as prostate cancer or general pathology workflow improvements. Hologic's Genius Digital Diagnostics System also represents an AI-powered cytology solution for gynecologic cytology.
The specific pricing models for AIxMed Computational Cytology are not publicly detailed. However, implementing AI tools in laboratories can involve significant costs related to digital cytopathology scanners, robust computational infrastructure, and personnel training.
A primary limitation is that AIxMed's AIxUROu2122 is currently for Research Use Only (RUO) and not for diagnostic procedures. Additionally, while AI can improve efficiency and accuracy, concerns exist about potential deskilling of experts and the need for further validation with larger clinical datasets.
AIxMed's platform digitizes 3D cytology samples and extracts quantitative and qualitative data. Its AIxUROu2122 application, for example, accurately identifies suspicious and atypical cells, highlights and ranks cells of interest, and provides detailed slide-level statistics and morphological data, which can lead to more efficient and accurate diagnoses and potentially reduce the need for invasive procedures.
AIxMed's primary application, AIxUROu2122, is specifically designed to assist in the analysis of non-invasive urine cytology specimens for bladder cancer diagnosis and surveillance, utilizing The Paris System for Reporting Urinary Cytology (TPS).
Suggest an Edit →
| Last Verified: 2026-08-23 | First Added: 2026-08-23